NCT04676061View on ClinicalTrials.gov

Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™

PHASE4TerminatedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

March 10, 2023

Conditions
Birth ControlContraceptionImplantBreakthrough BleedingUterine Bleeding
Interventions
DRUG

Norethindrone acetate (NTA)

norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks

DRUG

Placebo

Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks

Trial Locations (1)

76502

Baylor Research Institute, Temple

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Baylor Research Institute

OTHER